Genes · 2023 · 47 citations · 44 references
MedicineMolecular BiologyOncologyAutophagyGene ExpressionMolecular OncologyAutophagy In CancerCancer BiomarkersCancer GenomicsCancer TranscriptomicsMalignant NeoplasmsPancreatic CancerLassoLasso RegressionMolecular Prognostic MarkersPrognostic Expression SignaturesPrognostic Gene SignaturesPrognostic Rna BiomarkersPrognostic Tumor MarkersTumor Biomarker Discovery
Pancreatic adenocarcinoma (PAAD) is a common, highly malignant, and aggressive gastrointestinal tumor. The conventional treatment of PAAD shows poor results, and patients have poor prognosis. The synthesis and degradation of proteins are essential for the occurrence and development of tumors. Aggrephagy is a type of autophagy that selectively degrades aggregated proteins. It decreases the formation of aggregates by degrading proteins, thus reducing the harm to cells. By breaking down proteins, it decreases the formation of aggregates; thus, minimizing damage to cells. For evaluating the response to immunotherapy and prognosis in PAAD patients, in this study, we developed a reliable signature based on aggrephagy-related genes (ARGs). We obtained 298 AGGLncRNAs. Based on the results of one-way Cox and LASSO analyses, the lncRNA signature was constructed. In the risk model, the prognosis of patients in the low-risk group was noticeably better than that of the patients in the high-risk group. Additionally, the ROC curves and nomograms validated the capacity of the risk model to predict the prognosis of PAAD. The patients in the low-risk and high-risk groups showed considerable variations in functional enrichment and immunological analysis. Regarding drug sensitivity, the low-risk and high-risk groups had different half-maximal inhibitory concentrations (IC50).
44
Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2020 · 21.4K citations · Full text
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Dung T. Le, Jennifer N. Uram, Hao Wang et al. · New England Journal of Medicine · 2015 · 9.4K citations · Full text
Life Sciences, Immunology, Oncology +17
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Naiyer A. Rizvi, Matthew D. Hellmann, Alexandra Snyder et al. · Science · 2015 · 7.9K citations
Medicine, Immunology, Oncology +17
TIMER2.0 for analysis of tumor-infiltrating immune cells
Taiwen Li, Jingxin Fu, Zexian Zeng et al. · Nucleic Acids Research · 2020 · 5.7K citations · Full text
Medicine, Bioinformatics, Oncology +17
xCell: digitally portraying the tissue cellular heterogeneity landscape
Dvir Aran, Zicheng Hu, Atul J. Butte · Genome biology · 2017 · 4.7K citations · Full text